Appendix B. Sources of evidence considered by the Committee

Appendix B. Sources of evidence considered by the Committee

The following documentation and opinions were made available to the Committee:

A The Assessment Report for this appraisal was prepared by the Peninsula Technology Assessment Group, University of Exeter, and Southampton Health Technology Assessment, Wessex Institute for Health Research and Development, University of Southampton.

I Dalziel K, Round A, Stein K et al. The effectiveness and cost-effectiveness of imatinib for first line treatment of chronic myeloid leukaemia in chronic phase, 28 March 2003

B The following organisations accepted the invitation to participate in this appraisal. They were invited to make submissions and comment on the draft scope, Assessment Report and the Appraisal Consultation Document (ACD). Consultee organisations were provided with the opportunity to appeal against the Final Appraisal Determination.

I Manufacturer/sponsors:

  • Novartis Pharmaceuticals UK Ltd

II Professional/specialist and patient/carer groups:

  • British Committee on Standards in Haematology (British

  • Society for Haematology)

  • British Oncology Pharmacy Association

  • CancerBACUP

  • Cancer Research UK


  • Department of Health

  • Joint Collegiate Council for Oncology (Royal College of Physicians and the Royal College of Radiologists)

  • Leukaemia CARE

  • Leukaemia Society (UK)

  • Macmillan Cancer Relief

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal Pharmaceutical Society of Great Britain

  • Welsh Assembly Government

III Commentator organisations (without the right of appeal):

• British National Formulary

• Institute of Cancer Research

• Leukaemia Research Fund

• MRC Clinical Trials Unit

• NHS Confederation

• NHS Quality Improvement Scotland

C The following individuals were selected from clinical expert and patient advocate nominations from the professional/ specialist and patient/carer groups. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on imatinib by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Professor Michael Barnett, Professor of Transplantation Oncology, St Bartholomew's, London

  • Ms Sandy Craine, Patient Advocate and co-founder of

  • Ms Margaret Edgar, Patient Advocate, British Society for Haematology

  • Dr Steven O'Brien, Consultant Haematologist, Royal Victoria Infirmary, Newcastle upon Tyne

  • Ms Elizabeth Rees, Patient Advocate,

  • Dr Simon Rule, Consultant Haematologist, Derriford Hospital, Plymouth

  • Dr Pat Shepherd, Consultant Haematologist, Western General Hospital, Edinburgh